证券代码：003020 证券简称：立方制药 公告编号：2025-061 合肥立方制药股份有限公司 股票交易异常波动公告 三、不存在应披露而未披露信息的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 合肥立方制药股份有限公司（以下称"公司"）（股票简称：立方制药，股票代 码：003020）股票于 2025 年 8 月 15 日、2025 年 8 月 18 日、2025 年 8 月 19 日连续 三个交易日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规则》 的相关规定，属于股票交易异常波动情形。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司董事会对公司、控股股东和实际控制人就相 关事项进行了核实，有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、公司、控股股东及实际控制人不存在关于公司的应披露而未披露的重大事项， 或处于 ...

Group 1 - The core viewpoint of the articles highlights a significant surge in the innovative drug sector, with companies like Shenlian Bio and Boji Pharmaceutical reaching their historical highs, indicating a shift from "follower" to "leader" in China's innovative drug industry [1] - The current phase of China's innovative drug industry is identified as the 3.0 era, with expectations for 2025 to be a pivotal year for the overseas explosion of Chinese innovative drugs, with many products projected to exceed peak sales of $3 billion to $5 billion [1] - The investment opportunities in the innovative drug sector this year are anticipated to be greater than those in 2020-2021, driven by ongoing advancements and record-breaking licensing transactions [1] Group 2 - The National Medical Insurance Administration has recently published the preliminary list of drugs for the 2025 National Medical Insurance Drug Directory and commercial insurance innovative drug directory, with several cancer drugs and new drugs in chronic disease areas passing initial reviews [2] - The innovative drugs set to be included in the medical insurance and commercial insurance directories are mostly at a low base stage, suggesting potential for rapid growth as policy support continues to be released [2] - As the mid-year reporting season approaches, there are recommendations for investment opportunities based on the performance of companies in the second half of the year [2]

Company Performance - Lifan Pharmaceutical's stock price reached a historical high, increasing by 6.45% to 35.81 yuan, with a trading volume of 2.0682 million shares and a transaction value of 73.2369 million yuan, resulting in a turnover rate of 1.50% [2] - The company's latest A-share total market capitalization is 6.81 billion yuan, with a circulating market capitalization of 4.932 billion yuan [2] Industry Overview - The pharmaceutical and biotechnology industry has an overall increase of 0.50%, with 300 stocks rising, including notable gainers such as Furuide Co., Norsland, and Jimin Health, which saw increases of 18.46%, 10.98%, and 10.00% respectively [2] - Conversely, 176 stocks in the industry experienced declines, with the largest drops seen in Guangyuyuan, Haochen Medical, and Meihao Medical, which fell by 5.19%, 4.01%, and 3.45% respectively [2] Financial Results - In the first quarter, the company reported a total revenue of 360 million yuan, reflecting a year-on-year growth of 7.98% [2] - The net profit for the same period was 38.2503 million yuan, representing a year-on-year increase of 25.94%, with basic earnings per share of 0.2000 yuan and a weighted average return on equity of 2.18% [2]

Market Overview - The A-share market continued to rebound, with the Shanghai Composite Index rising by 0.44%, the Shenzhen Component Index by 0.57%, and the ChiNext Index by 1.04% as of 9:45 AM on August 19 [1] - The pharmaceutical sector showed strong performance, particularly in innovative drugs, with Ji Min Health hitting the daily limit [1] - AI hardware stocks like New Yisheng and Zhongji Xuchuang reached historical highs, while sectors such as film, media, military, banking, oil and gas, and wind power experienced declines [1] Key Sectors Innovative Drug Sector - The innovative drug sector saw significant gains, with Ji Min Health and Kangyuan Pharmaceutical hitting the daily limit, and other companies like Nuo Si Lan De and Li Fang Pharmaceutical also rising [2] - CITIC Securities reports a favorable policy environment for innovative drugs starting from 2025, recommending investments in innovation-driven and internationalization strategies, particularly in the innovative drug field [2] CPO Concept - CPO concept stocks maintained strong performance, with New Yisheng and Zhongji Xuchuang reaching historical highs, and companies like Jianqiao Technology and Tengjing Technology also seeing gains [3] - CITIC Jiantou Securities highlights a shift in AI training network architecture, leading to increased demand for optical modules, with 800G optical modules expected to see significant growth starting in 2023 [3] Institutional Insights Shenwan Hongyuan - Shenwan Hongyuan believes the short-term bull market atmosphere will continue to dominate, with a focus on securities, insurance, military, and rare earth sectors before early September [4] - The firm emphasizes the importance of sectors with scarce overseas computing power and suggests a price alliance in high market share manufacturing segments [4] Huatai Securities - Huatai Securities suggests that the market may have entered the mid-stage of a bull market, characterized by structural features and rapid sector rotation [5] - The firm notes that the current slow bull market may extend the upward cycle, with a need for increased market signals to attract more external funds [5] Dongfang Securities - Dongfang Securities anticipates no major adjustment risks for stock indices in August, with a "local advance, multi-point bloom" characteristic in the current market [6] - The firm advises caution against potential pullbacks and emphasizes the importance of "high-low switching" in the event of market adjustments, recommending focus on technology autonomy, innovative drugs, military, and robotics sectors [6]

Company Overview - Hefei Lifang Pharmaceutical Co., Ltd. was established in 2002 and is located in Hefei City, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 1,901.82182 million RMB and a paid-in capital of 660 million RMB [1] Investment and Intellectual Property - Hefei Lifang Pharmaceutical has invested in 11 companies and participated in 5,000 bidding projects [1] - The company holds 89 trademark registrations and 88 patent registrations, along with 597 administrative licenses [1] Shareholder Information - Major shareholders include Ji Junqiu with 67.41% ownership, Deng Xiaojun with 10%, Gao Meihua with 5.34%, Li Xiaochang with 4.64%, and Cai Ying with 2% [1] Regulatory Communication - The company has applied for a "Type III meeting" with the CDE, which is currently in process, and such meetings are typically held within 75 days after the application [1]

证券日报网讯 8月12日晚间，立方制药发布公告称，公司第五届董事会第二十二次会议审议通过了《关 于修订〈公司章程〉并办理工商登记的议案》等多项议案。 （文章来源：证券日报） ...

立方制药（SZ 003020，收盘价：28.72元）8月12日晚间发布公告称，公司第五届第二十二次董事会会 议于2025年8月12日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于修订〈公司章程〉 并办理工商登记的议案》等文件。 2024年1至12月份，立方制药的营业收入构成为：医药工业占比90.69%，医药零售占比7.28%，其他业 务占比2.03%。 （文章来源：每日经济新闻） ...

公司股东会的召集、提案、通知、召开等事项适用本规则。 第二条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相 关规定召开股东会，保证股东能够依法行使权利。 股东会议事规则 合肥立方制药股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范合肥立方制药股份有限公司（以下简称"公司"）行为， 保证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称《公司 法》）《中华人民共和国证券法》（以下简称《证券法》）《上市公司股东会 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》（以下《规范运作指引》）等法律、行政法规、部门规章、规范性文件 及《合肥立方制药股份有限公司章程》（以下简称《公司章程》）的规定，制 定本规则。 1 股东会议事规则 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应 当忠实、勤勉、尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的 6 个月内举行。临时股东会不定期召开。出现《公 ...

战略委员会工作细则 合肥立方制药股份有限公司 战略委员会工作细则 第一章 总则 第一条 为适应合肥立方制药股份有限公司（以下简称"公司"）战略发展 需要，增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加强决 策科学性，提高重大投资效益和决策质量，完善公司治理结构，根据《中华人 民共和国公司法》（以下简称《公司法》）《上市公司治理准则》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《合肥立 方制药股份有限公司章程》（以下简称《公司章程》）及其他有关规定，公司 设立董事会战略委员会（以下简称"战略委员会"），并制定本细则。 第二条 战略委员会是董事会下设的专门工作机构，主要负责对公司中长期 发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会由三名董事组成，其中至少包括一名独立董事。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一以上（含三分之一）提名并由董事会选举产生，经董事会表决，二分 之一以上董事同意方可当选。选举委员的提案获得通过后，新任委员在董事会 会议结束后立即就任。 第五条 战略委员会设主任委员（召集人 ...

审计委员会工作细则 合肥立方制药股份有限公司审计委员会工作细则 第一章 总 则 第一条 为强化合肥立方制药股份有限公司（以下简称"公司"）董事会决 策功能，做到事前审计、专业审计,确保董事会对管理层的有效监督，完善公司 治理结构，根据《中华人民共和国公司法》（以下简称《公司法》）、《上市公 司治理准则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》《合肥立方制药股份有限公司章程》（以下简称《公司章程》）及其 他有关规定，公司设立董事会审计委员会（以下简称"审计委员会"），并制定 本细则。 第二条 审计委员会是董事会下设的专门工作机构，主要职能是协助董事会 独立审查公司财务状况、内部监控及风险管理制度的执行情况及效果，出具内部 管理建议书，以及与公司内、外部审计的独立沟通、监督和核查工作。 第二章 人员组成 审计委员会工作细则 第七条 公司设立审计部，审计部在审计委员会的指导和监督下开展内部审 计工作。董事会秘书负责审计委员会和董事会之间的具体协调工作。 第三章 职责权限 第八条 审计委员会的主要职责权限： 第三条 审计委员会由三名不在公司担任高级管理人员的董事组成，其中独 立董事两 ...